Akeso reported record commercial sales revenue of approximately RMB 1,803.2 million for the first half of 2026, up 28.7% from a year earlier. Cash, cash equivalents and other short-term financial assets totaled RMB 9,160.0 million as of the reporting date. By the end of 2025, all 12 indications across five self-commercialized innovative drugs had been added to China’s National Reimbursement Drug List (NRDL), including two non-small cell lung cancer indications for ivonescimab and three cervical and gastric cancer indications for cadonilimab. In August 2026, China’s National Medical Products Administration (NMPA) approved ivonescimab plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer. Akeso said it is building a global IO2.0 strategy around ivonescimab and cadonilimab, with more than 17 registrational Phase II/III studies for ivonescimab and more than 13 registrational or Phase III studies for cadonilimab. The company is also developing an IO2.0 plus ADC2.0 therapeutic matrix, combining its immuno-oncology bispecific antibodies with proprietary and partnered antibody-drug conjugates. Its broader pipeline includes bispecific and multispecific antibodies for autoimmune, respiratory and central nervous system disorders, as well as AI-enabled drug discovery programs. Akeso said the candidates and commercial plans described in the announcement remain subject to regulatory, development, manufacturing, market and other risks.